Skip to main content
74 search results for:

Cyclophosphamide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 15-11-2022 | ACR 2022 | Conference coverage | Article

    RECITAL: Rituximab represents alternative to cyclophosphamide for CTD-ILD

    Rituximab and cyclophosphamide have similar overall efficacy in patients with connective tissue disease-associated interstitial lung disease, but rituximab may be associated with fewer adverse events, suggest findings from a phase 2b trial.

  2. 01-04-2022 | Lupus nephritis | News | Article

    Trial supports tacrolimus as an alternative to cyclophosphamide for lupus nephritis

    Phase 3 trial results suggest that the calcineurin inhibitor tacrolimus may represent an alternative option to cyclophosphamide for the initial treatment of lupus nephritis.

  3. 26-07-2018 | Scleroderma | Article

    Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

    Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

  4. 03-07-2018 | Vasculitis | Article

    Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: A retrospective observational study

    To describe the use of oral cyclophosphamide (PO CYC) in a single center longitudinal cohort of patients with idiopathic inflammatory myopathies.

  5. 14-10-2022 | Systemic sclerosis | News | Article

    Men may have a more severe SSc-ILD disease course than women

    The study, published in The Lancet Rheumatology , included 158 participants treated with cyclophosphamide or placebo in SLS I and 142 participants who were given cyclophosphamide or mycophenolate mofetil in SLS II.

  6. 15-09-2022 | Systemic lupus erythematosus | News | Article

    Male sex, older age risk factors for acute kidney abnormalities in childhood SLE

    They found that, during the induction period (30 days before and 60 days after initial kidney biopsy), mycophenolate was the most commonly used DMARD (40%), followed by cyclophosphamide (12%), cyclophosphamide plus rituximab (8%), rituximab (7%), hydroxychloroquine (7%), and other DMARDs (5%).

  7. 22-07-2022 | Lupus nephritis | News | Article

    Leflunomide shows promise in lupus nephritis

    Their study included 270 individuals with biopsy-confirmed active lupus nephritis from seven Chinese rheumatology centers who were initially given induction therapy with intravenous cyclophosphamide plus glucocorticoids for 6 to 9 months.

  8. 28-01-2022 | COVID-19 | Video | Article

    Rituximab use in the COVID-19 era: Striking the right balance

    We're using a little bit more cyclophosphamide.

  9. 19-11-2021 | ANCA-associated vasculitis | News | Article
    approvalsWatch

    Avacopan: EMA recommends approval for ANCA-associated vasculitis

    medwireNews : The EMA has recommended approval of avacopan, when used in combination with rituximab or cyclophosphamide, for the treatment of two forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

  10. 01-03-2021 | COVID-19 | Feature | Article

    COVID-19 vaccination in patients with rheumatic diseases

    However, there are some exceptions, namely rituximab, methotrexate, Janus kinase inhibitors, abatacept, and cyclophosphamide, for which guidance is given.

  11. 27-10-2021 | ANCA-associated vasculitis | News | Article
    approvalsWatch

    FDA approves avacopan for ANCA-associated vasculitis

    The efficacy of avacopan for ANCA-associated vasculitis was shown in the phase 3 ADVOCATE trial , which compared remission rates with the C5a receptor inhibitor versus placebo when added to standard treatment with rituximab or cyclophosphamide followed by azathioprine. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

  12. 10-07-2021 | Adis Journal Club | Article
    Pediatric Drugs

    An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

    Mycophenolate mofetil or intravenous cyclophosphamide is suggested as induction therapy for lupus nephritis classes III and IV.

  13. 07-07-2021 | Rituximab | News | Article

    Positive risk–benefit profile for rituximab in pediatric GPA and MPA

    Writing in Arthritis & Rheumatology , Paul Brogan (UCL Great Ormond Street Institute of Child Health, London, UK) and co-authors explain that “[r]ituximab is increasingly being used as a first-line remission induction treatment in children with [anti-neutrophil cytoplasmic antibody-associated vasculitides] instead of cyclophosphamide.”

  14. 05-06-2020 | EULAR 2020 | Conference coverage | Article

    Phase 3 results ADVOCATE C5a receptor inhibition for ANCA-associated vasculitis

    Peter Merkel_040620 The rate of remission at week 26 – defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and no glucocorticoid treatment within the past 4 weeks – was 72.3% for the 166 participants who were randomly assigned to receive avacopan 30 mg twice daily alongside prednisone placebo and standard treatment with rituximab or cyclophosphamide followed by azathioprine.

  15. 08-04-2021 | COVID-19 | News | Article
    News in brief

    Risk factors for severe COVID-19 identified in patients with systemic vasculitis

    Conversely, vasculitis disease activity and the use of non-glucocorticoid immunosuppressants, such as rituximab and cyclophosphamide, were not significantly associated with severe outcomes.

  16. 25-03-2021 | Lupus nephritis | News | Article

    High prednisone dose, rapid tapering may be favorable in new-onset lupus nephritis

    As reported in Arthritis Care & Research , similar results were observed in analyses of various subgroups, including patients with proliferative and non-proliferative disease, those who received mycophenolate mofetil or cyclophosphamide, and patients with sub-nephrotic proteinuria.

  17. 02-02-2021 | Lupus nephritis | News | Article
    approvalsWatch

    Voclosporin approved for lupus nephritis in the USA

    Voclosporin is indicated for use alongside background immunosuppressive treatment with mycophenolate mofetil and corticosteroids, but is not recommended alongside cyclophosphamide.

  18. 24-04-2020 | COVID-19 | News | Article

    Rheumatologists, patients report healthcare changes during COVID-19 pandemic

    A total of 64.2% of the healthcare providers said they were less inclined to change a patient’s major immunosuppressant for impending flare than they were before the emergence of COVID-19; the most frequently deferred treatment was rituximab, followed by cyclophosphamide, tumor necrosis factor inhibitors, Janus kinase inhibitors, and other biologics.

  19. 08-09-2020 | Systemic lupus erythematosus | News | Article

    Cancer risk factors described for patients with SLE

    They add: “Interestingly, none of the lung cancer cases had been exposed to cyclophosphamide or methotrexate, and all had been exposed to antimalarial agents for at least 5 years; this precluded us being able to calculate specific estimates of risk for lung cancer for these agents.”

  20. 05-06-2020 | EULAR 2020 | Conference coverage | Article

    Belimumab shows promise for lupus nephritis

    Furie reported that “there were no outstanding safety issues” in the BLISS-LN trial, “despite the fact that belimumab was added to background therapy consisting of mycophenolate or cyclophosphamide along with sterioids.”

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.